Mushroom boardroom: Why some execs are using psychedelics to get through the workday
This is a preview of a story that was initially published on our sister site, WorkLife, which covers the future of the workplace.
After his father died in 2018, Paul Marlow struggled with fear, anxiety and depression. That’s when he turned to microdosing psychedelics as a remedy — and he hasn’t looked back.
Microdosing, he said, helps him focus at work. As the pandemic persists, many who are looking for a jolt of motivation, inspiration or medication are turning to microdosing — that is, ingesting small amounts of psychedelic drugs to combat mental health issues and enhance creativity, productivity and physical well-being. Read the full story on WorkLife.
More in Marketing
Digiday+ Research: The 2026 guide to holiday marketing strategies, including A-Frame Brands, Mastercard and Ritual
Shoppers continue to grapple with higher prices and affordability, while brands face rising operating costs and increased pressure to prove their marketing dollars are delivering measurable returns.
Inside the indie agencies founded by Omnicom and IPG’s former staffers
Thousands of media practitioners and creatives have left Omnicom since its merger with IPG. Some have already founded their own agencies.
Who owns the creative brief? Brands and creators are renegotiating the relationship
Brands are moving creators beyond sponsored posts and into the creative process, reshaping who influences marketing decisions.